# Pallas Health reviews (2026): GLP-1 telehealth sellers | This GLP The monthly figure is an average the seller publishes itself: one discounted first month, then a charge every twelve weeks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pallas-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Billed every twelve weeks # Pallas Health review The monthly figure is an average the seller publishes itself: one discounted first month, then a charge every twelve weeks. ## The verdict Pallas Health charges $139 for a first month of compounded semaglutide and $597 every twelve weeks after it, which the seller averages to $199 a month. Twelve weeks is 2.76 calendar months rather than three, so the figure ranked here is $216. Tirzepatide works out at $325 on the same arithmetic. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $216/mo Prescription Required Compounded Yes — not FDA-approved Pallas Health sells compounded semaglutide and compounded tirzepatide as weekly injections across fifty states and the District of Columbia, and the billing shape is the first thing worth understanding. A reader pays $139 to start on semaglutide, and from then on the card is charged $597 at a time, twelve weeks apart. Provider care and check-ins are described as included in that figure, and the rate is stated as the same at every dose. 1. ## Who writes the prescription, and what do they see? Check-ins are inside the price rather than billed against a visit, which changes what the twelve-week charge is actually buying — it is a quarter of care rather than a quarter of medication. That distinction matters most in the second quarter, when a reader is usually deciding whether to stay at a dose or move up. How often the check-ins happen, and whether they are live or asynchronous, is not something the priced row establishes. Treatment is arranged remotely and the medication arrives on a schedule tied to the twelve-week block rather than to a calendar month. The first month is deliberately cheap, which is a good thing for a reader who wants to find out how the drug suits them, and a slightly awkward thing when it is averaged into a headline. The seller does the averaging in public, on the page, rather than leaving the reader to discover the real cadence at the second charge. 2. ## What happens when the dose goes up? The rate is stated as the same at every dose on both molecules, so the escalation that runs through the first sixteen weeks does not move the bill. What does move is the timing: the first dose increase usually lands inside the first twelve-week block, and the second charge arrives whether or not the drug has suited the reader. A quarter is a long commitment at the exact point most people are still deciding. 3. ## What the price includes The averaging is where the seller and this desk part company, and the gap is small but real. Twelve weeks is 2.76 calendar months rather than three, so $597 every twelve weeks is $216 a calendar month and not the $199 the page advertises. The tirzepatide block at $897 works out at $325 on the same arithmetic rather than $299. The first-month figures of $139 and $179 make the opening quarter cheaper than the ones after it, so a reader budgeting from the first charge will underestimate the second. 4. ## What it claims, and what it cites Both products are compounded, which means a pharmacy prepares them rather than a manufacturer, and no regulator reviews the finished vial before it is dispensed. A reader who has seen the published weight-change figures for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) should know those came from the approved product at the doses on its label. Whether a compounded vial matches that product in content or purity is not measured, and no billing arrangement changes that. ## Where it holds up, and where it does not - Strength: Seller publishes its own averaging - Strength: Provider care and check-ins included - Strength: Rate stated as flat at every dose - Limitation: Card is charged $597 at a time - Limitation: First month is cheaper than the rest - Limitation: Twelve weeks is the shortest commitment ## What the evidence says about this kind of treatment The assessment above is about Pallas Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who expects to stay past the first quarter and wants provider check-ins inside the price rather than billed against each visit. Wrong for A reader who wants to pay by the month, because after the discounted start the smallest charge available is twelve weeks at a time. ## The evidence behind what Pallas Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Pallas Health compares | Seller | Who it suits | Go | | --- | --- | --- | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [KIN Health](https://thisglp.com/reviews/kin-health) [Klarity Health](https://thisglp.com/reviews/klarity-health) [Klinic](https://thisglp.com/reviews/klinic) [Kova](https://thisglp.com/reviews/kova) [LifeVine Wellness](https://thisglp.com/reviews/lifevine-wellness) [Lighter You](https://thisglp.com/reviews/lighter-you) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 a month what the card is charged? No. After a $139 first month the card is charged $597 every twelve weeks. Pallas divides that by three and advertises $199; twelve weeks is 2.76 calendar months, so the figure ranked here is $216. What happens if the treatment does not suit me? The first month is $139, and the next charge is a full twelve-week block. A reader who stops in month two has paid the lowest figure on the page; one who stops in month four has already paid for a quarter. Does the price change as the dose rises? Pallas states the same price at every dose on both molecules, so the escalation across the first sixteen weeks leaves the figure alone. Is Pallas Health expensive compared with other GLP-1 telehealth sellers? Pallas Health publishes a starting figure of $216/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Pallas Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).